European Archives of Psychiatry and Clinical Neuroscience
November 17, 2024
Anastasia Demina, Benjamin Petit, Vincent Meille et al.
6 citations
In this article we aimed synthesize all available evidence regarding the effects of non-invasive brain stimulation (NIBS) techniques combined with mindfulness-based interventions (MBIs) on mental health indicators. We performed a systematic review of randomized controlled trials evaluating NIBS/MBIs combinations in clinical populations and a random effects pairwise meta-analysis of studies...
Biomedicines
November 15, 2024
Andrea Calderone, Desirèe Latella, Federica Impellizzeri et al.
83 citations
Background and Objectives: Meditation and mindfulness, rooted in ancient traditions, enhance mental well-being by cultivating awareness and emotional control. It has been shown to induce neuroplasticity, increase cortical thickness, reduce amygdala reactivity, and improve brain connectivity and neurotransmitter levels, leading to improved emotional regulation, cognitive function, and stress...
Discover Psychology
November 3, 2024
Joshua W. Bryan
3 citations
Abstract Ketamine, often associated with its frequent illicit recreational use, is renowned as an approved alternative for treatment-resistant depression. This paper evaluates the mechanism of ketamine’s role in treating depression, emphasising its positive safety profile and acute onset of action. Ketamine’s mechanism of action involves antagonism of N-methyl-D-Aspartate (NMDA) receptors,...
Neuroscience
November 1, 2024
Vishal Bharmauria, Hamidreza Ramezanpour, Afef Ouelhazi et al.
Ketamine is a widely used clinical drug that has several functional and clinical applications, including its use as an anaesthetic, analgesic, anti-depressive, anti-suicidal agent, among others. Among its diverse behavioral effects, it influences short-term memory and induces psychedelic effects. At the neural level across different brain areas, it modulates neural firing rates, neural tuning,...
Trends in Neurosciences
November 1, 2024
Cecilia Anna Brunello, Cecilia Cannarozzo, Eero Castrén
29 citations
Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neuronal receptor tyrosine kinase 2 (NTRK2 or TRKB) is among the critical steps in this process. These mechanisms are shared by typical slow-acting antidepressants, fast-acting ketamine, and psychedelic compounds, although the cellular targets of each drug...
Neuropsychopharmacology
November 1, 2024
Ruth H Asch, Chadi G. Abdallah, Richard E. Carson et al.
11 citations
The development of novel radiotracers for Positron Emission Tomography (PET) imaging agents targeting the synaptic vesicle glycoprotein 2 A (SV2A), an integral glycoprotein present in the membrane of all synaptic vesicles throughout the central nervous system, provides a method for the in vivo quantification of synaptic density. This is of particular interest in neuropsychiatric disorders given...
Philosophical transactions of the Royal Society of London. Series B, Biological sciences
October 21, 2024
Stefanie Enriquez‐geppert, Jaroslav Krc, Fiachra O'Higgins et al.
5 citations
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting treatment and training responsiveness. In this pioneering study, we evaluated the feasibility and preliminary efficacy of psilocybin-assisted frontal-midline theta neurofeedback (NF), a neuromodulation technique leveraging neuroplasticity, to improve...
The International Journal of Neuropsychopharmacology
October 1, 2024
Nicholas E Bulthuis, Josephine C McGowan, Liliana R Ladner et al.
2 citations
Standard antidepressant treatments often take weeks to reach efficacy and are ineffective for many patients. (R,S)-ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be a rapid-acting antidepressant and to decrease depressive symptoms within hours of administration. While previous studies have shown the importance of the GluN2B subunit of the NMDA receptor on...
European Archives of Psychiatry and Clinical Neuroscience
September 29, 2024
Ege T Kavalali, Lisa M Monteggia
4 citations
The discovery of ketamine's rapid antidepressant action has generated intense interest in the field of neuropsychiatry. This discovery demonstrated that to alleviate the symptoms of depression, treatments do not need to elicit substantive alterations in neuronal circuitry or trigger neurogenesis, but rather drive synaptic plasticity mechanisms to compensate for the underlying pathophysiology....
Neuroscience & Biobehavioral Reviews
September 20, 2024
Isabel Werle, Leandro J Bertoglio
17 citations
Threatening events and stressful experiences can lead to maladaptive memories and related behaviors. Existing treatments often fail to address these issues linked to anxiety/stress-related disorders effectively. This review identifies dose ranges associated with specific actions across various psychedelics. We examined psilocybin/psilocin, lysergic acid diethylamide (LSD),...